Core Insights - Silexion Therapeutics has completed the data collection phase for its first evaluation of SIL-204 in clinically relevant orthotopic pancreatic cancer models, marking a significant milestone in its development program [1][2][3] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers, with its first-generation product, LODER™, showing promising results in Phase 2 trials for non-resectable pancreatic cancer [4] - The company is advancing its next-generation siRNA candidate, SIL-204, which targets a broader range of KRAS mutations [4] Study Details - The study evaluated SIL-204's ability to reduce primary tumor growth and metastatic spread in orthotopic pancreatic cancer models, which better reflect human pancreatic cancer biology compared to traditional subcutaneous xenograft models [2][6] - The orthotopic models allow for a more accurate assessment of tumor behavior and therapeutic efficacy against both primary and metastatic disease [2] Future Expectations - Initial results from the study are expected to be reported in March 2025, which will inform Silexion's development strategy for SIL-204 [3]
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204